Dr Reddy’s introduces generic cancer drug Invista in india Kumar Jeetendra | April 13, 2020 Pharma major Dr Reddy’s Laboratories Ltd has propelled Invista. It is a detailing of Dasatinib that is bioequivalent to the pioneer brand. Patent on Dasatinib is possessed by Bristol-Myers-Squibb. The Indian patent has lapsed on April 12, 2020. It is demonstrated for the treatment of ceaseless quickened or myeloid or lymphoid impact stage and recently …
Cipla receives final approval for generic version of inhalation drug Kumar Jeetendra | April 9, 2020 Mumbai, India; April 9, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA). Cipla’s Albuterol Sulfate Inhalation Aerosol …
West Pharmaceutical Names Stewart Campbell Vice President & General Manger for Asia Pacific Region Kumar Jeetendra | April 8, 2020 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, recently named Stewart Campbell as the Vice President & General Manager for the Asia Pacific region. Stewart brings more than 25 years of organizational leadership in the food, pharmaceutical and dietary supplement industries, with extensive Asia Pacific management expertise. …
World First Clinical Study of iPSC-derived Corneal Epithelial Cells Kumar Jeetendra | April 6, 2020 AMSBIO report on a world first clinical study of iPSC-derived corneal epithelial cells by Professor Ryuhei Hayashi and co-workers from the Graduate School of Medicine, Osaka University, Japan using StemFit Basic03 clinical grade stem cell culture medium and iMatrix-511 recombinant laminin E8 fragments. In this ground-breaking work, corneal epithelial sheets from HLA-homozygous iPS cells were …
Cipla reports fruitful completion of Phase-3 clinical examination for generic version of GSK’s Advair Diskus® Kumar Jeetendra | April 2, 2020 Cipla Limited today declared the fruitful completion of Phase-3 clinical end-point concentrate for fluticasone propionate and salmeterol inward breath powder (100/50 mcg). Fluticasone propionate and salmeterol inward breath powder 100/50 mcg, 250/50 mcg and 500/50 mcg are nonexclusive adaptations of GSK’s Advair Diskus®. The item is shown to treat asthma in patients 4 years and …
Danaher finishes procurement of GE Healthcare’s Life Sciences division Kumar Jeetendra | April 1, 2020 New Danaher working organization made after fruition of $21.4B securing by Danaher Corporation – Previously GE Healthcare Life Sciences, Cytiva will help quicken development and advancement in natural treatments – Leading life sciences brands, for example, ÄKTA, Amersham, HyClone, MabSelect and Whatman are a piece of Cytiva Cytiva, a worldwide supplier of innovations and administrations …
Intas to give 2 million hydroxychloroquine tablets to WHO focus on COVID-19 Kumar Jeetendra | March 30, 2020 Intas Pharmaceuticals Ltd. has said it will give up to 2,000,000 tablets of hydroxychloroquine to World Health Organization-supported examination into the avoidance of COVID-19 contamination utilizing hydroxychloroquine, for nothing out of pocket, alongside 2,000,000 tablets of coordinated fake treatment. Intas educated that it is teaming up on the WHO-embraced study utilizing hydroxychloroquine, a medication that …
Malaria drug is greatest expectation against coronavirus-Novartis CEO Kumar Jeetendra | March 29, 2020 Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit’s jungle fever, lupus and joint pain tranquilize hydroxychloroquine is the organization’s greatest expectation against the coronavirus, Swiss paper SonntagsZeitung gave an account of Sunday. Novartis has vowed to give 130 million dosages and is supporting clinical preliminaries required before the medication, which U.S. President Donald …
Restrictions on export of key Malaria drug in the midst of coronavirus episode Kumar Jeetendra | March 25, 2020 The Indian government said on Wednesday that it is forbidding the fare of hydroxychloroquine and plans produced using the medicine, as specialists test the viability of the medication in helping treat patients contaminated with Covid-19. There are at present no endorsed medications, or preventive immunizations for Covid-19, the profoundly infectious, once in a while savage …
First Made-in-India COVID-19 test pack by Mylab gets business endorsement Kumar Jeetendra | March 23, 2020 Pune-based sub-atomic diagnostics organization Mylab Discovery Solutions Pvt Ltd, which spends significant time in sub-atomic analytic units has grown originally made-in-India test pack for COVID-19 of every a record time of about a month and a half. The unit – Mylab PathoDetect COVID-19 Qualitative PCR pack – is the first to get business endorsement from …
Mumbai based IPCA gets a jolt as USFDA suspends import boycott for key Covid-19 medication Kumar Jeetendra | March 23, 2020 IPCA labs, one of the biggest provider of hostile to malarial medication Chloroquine and the Rheumatoid Artharitis tranquilize Hydroxychloroquine has got its import alert suspended as the USFDA by the USFDA made a special case to the organization due to the conceivable ascent sought after of these medications emerging out of the Covid-19 pandemic. “We …
Particle Characterization Software Kumar Jeetendra | March 19, 2020 The 2020 version of its Particle Solutions Software Suite is now available free of charge from Testa Analytical Solutions e.K for users of their NanoBrook series of particle characterization instruments. Carlo Dessy, Managing Director of Testa Analytical commented “In line with our total commitment to excellent customer support this latest version of our comprehensive particle …
